Experienced in Hemolytic Anemia

Isaac Yaniv

Petah Tiqwa, M, IL 
Experienced in Hemolytic Anemia
Petah Tiqwa, M, IL 
OverviewLocationsClinical Research

Overview

Isaac Yaniv practices in Petah Tiqwa, Israel. Mr. Yaniv is rated as an Experienced expert by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

His clinical research consists of co-authoring 90 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Hemolytic Anemia.

Gender
Male

Locations

Petah Tiqwa, M, Israel
Other Locations
Tel Aviv, TA, Israel
Jaffa, TA, Israel
Petach Tikvah, Israel
Ramat Aviv, TA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
Enrollment Status: Unknown
Publish Date: July 14, 2020
Intervention Type: Drug
Study Drugs: ch14.18/CHO, Aldesleukin, Isotretinoin
Study Phase: Phase 1/Phase 2

90 Total Publications

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.
Journal: Cancers
Published: July 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yaniv's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile